Company profile: Mainz Biomed
1.1 - Company Overview
Company description
- Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
Products and services
- ColoAlert: A PCR-based, non-invasive, at-home colorectal cancer screening product that detects tumor DNA in stool samples, delivering higher sensitivity and specificity than traditional fecal tests
- ReconAAsense: An FDA PMA pivotal study engineered to gain approval for Mainz Biomed’s next-generation colorectal cancer screening test in the US and to initiate international market launch
- EAArly DETECT: A multimodal screening product combining FIT, mRNA biomarkers, and AI algorithms to differentiate colorectal cancer, advanced adenomas, and non-advanced adenomas
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mainz Biomed
Modifi Bio
HQ: United States
Website
- Description: Provider of direct DNA modification cancer therapeutics, including orally delivered molecules that selectively kill cancer cells by modifying tumor DNA while preserving healthy cells. Products target cancers with DNA repair defects and MGMT deficiency, with applications in glioblastomas, gliomas, and potentially other MGMT-deficient tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modifi Bio company profile →
PharmaMar
HQ: Spain
Website
- Description: Provider of oncology medicines inspired by the sea, discovering antitumor molecules from marine organisms through integrated research and development. Delivers innovative products to equip healthcare professionals with new tools to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaMar company profile →
Serenex
HQ: United States
Website
- Description: Provider of medical drug discovery and development focused on oncology, developing an Hsp90 product platform with small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases such as Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serenex company profile →
Endomag
HQ: United Kingdom
Website
- Description: Provider of magnetic sensing technologies for breast cancer care, including the Sentimag surgical guidance system to detect tumors and lymph nodes, Magseed markers for precise tissue and lymph node localization, Magtrace lymphatic tracer for sentinel node biopsy with clear signal and visual guidance, and Magseed Pro self-expanding seed for precise deployment and anchoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endomag company profile →
DiaCarta
HQ: United States
Website
- Description: Provider of precision molecular diagnostics, including CE/IVD-marked KRAS detection, for cancer screening, monitoring, and therapy guidance. Offerings include RadTox for real-time cfDNA treatment response; ColoScape for colorectal screening and FIT-positive triage via plasma cfDNA changes; QClamp for sensitive ctDNA mutation detection; OptiSeq Colorectal Cancer NGS Panel for actionable mutations; Oncuria urine biomarkers; and custom mini-MRD panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaCarta company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mainz Biomed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mainz Biomed
2.2 - Growth funds investing in similar companies to Mainz Biomed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mainz Biomed
4.2 - Public trading comparable groups for Mainz Biomed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →